Amarin Corporation plc
AMRNHealthcareNASDAQDrug Manufacturers - General
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Amarin Corporation plc focuses on Drug Manufacturers - General services and products. Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and. With a market capitalization of $287.9M, it sits in micro-cap territory. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Market Cap
$287.9M
Beta
0.76
P/E (TTM)
—
P/E (Fwd)
13.91
EPS (TTM)
$-1.20
EPS (Fwd)
$0.98
ROE
-6.0%
ROA
-2.3%
Cash
$314.6M
Total Debt
$7.2M
Free CF
-$5.6M
52W Change
-10.4%
Annual Financials
Cash vs Debt
Where AMRN stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, AMRN finished 6.61% below its 150-day moving average ($14.67) and 7.24% below its 200-day moving average ($14.77). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is AMRN overbought or oversold?
At the September 3, 2026 close, AMRN's RSI(14) was 40.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Amarin Corporation plc holds $314.6M in cash against $7.2M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$5.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -6.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has pulled back from $583.2M (2021) to $213.6M (2025), a 63% decline worth watching.
With cash comfortably exceeding debt, AMRN has financial flexibility that may help navigate uncertain periods. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing AMRN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.